Cancer Research  CR Podcast
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alazzouzi, H.
Right arrow Articles by Arango, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alazzouzi, H.
Right arrow Articles by Arango, D.
[Cancer Research 65, 10170-10173, November 15, 2005]
© 2005 American Association for Cancer Research


Priority Reports

Mechanisms of Inactivation of the Receptor Tyrosine Kinase EPHB2 in Colorectal Tumors

Hafid Alazzouzi1, Veronica Davalos1, Antti Kokko2, Enric Domingo1, Stefan M. Woerner3, Andrew J. Wilson4, Lars Konrad3, Päivi Laiho2, Eloi Espín1, Manel Armengol1, Kohzoh Imai5, Hiroyuki Yamamoto5, John M. Mariadason4, Johannes F. Gebert3, Lauri A. Aaltonen2, Simo Schwartz, Jr.1 and Diego Arango1

1 Molecular Oncology and Aging Group, Molecular Biology and Biochemistry Research Center (CIBBIM), Valle Hebron Hospital Research Institute, Barcelona, Spain; 2 Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland; 3 Institute of Molecular Pathology/Applied Tumor Biology, University of Heidelberg, Heidelberg, Germany; 4 Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, New York; and 5 First Department of Internal Medicine, Sapporo Medical University, Sapporo, Japan

Requests for reprints: Diego Arango, Molecular Oncology and Aging Group, Molecular Biology and Biochemistry Research Center (CIBBIM), Valle Hebron Hospital Research Institute, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain. Phone: 34-93-489-4058; Fax: 34-93-489-4040; E-mail: darango{at}vhebron.net.

The receptor tyrosine kinase EPHB2 has recently been shown to be a direct transcriptional target of TCF/ß-catenin. Premalignant lesions of the colon express high levels of EPHB2 but the expression of this kinase is reduced or lost in most colorectal carcinomas. In addition, inactivation of EPHB2 has been shown to accelerate tumorigenesis initiated by APC mutation in the colon and rectum. In this study, we investigated the molecular mechanisms responsible for the inactivation of EPHB2 in colorectal tumors. We show here the presence of mutations in repetitive sequences in exon 17 of EPHB2 in 6 of 29 adenomas with microsatellite instability (MSI), and 101 of 246 MSI carcinomas (21% and 41%, respectively). Moreover, we found EPHB2 promoter hypermethylation in 54 of the 101 colorectal tumors studied (53%). Importantly, EPHB2 expression was restored after treatment of EPHB2-methylated colon cancer cells with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. In conclusion, in this study, we elucidate the molecular mechanisms of inactivation of EPHB2 and show for the first time the high incidence of frameshift mutations in MSI colorectal tumors and aberrant methylation of the regulatory sequences of this important tumor suppressor gene.




This article has been cited by other articles:


Home page
Mol Cancer ResHome page
J. Wykosky and W. Debinski
The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting
Mol. Cancer Res., December 1, 2008; 6(12): 1795 - 1806.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
M. Lackmann and A. W. Boyd
Eph, a Protein Family Coming of Age: More Confusion, Insight, or Complexity?
Sci. Signal., April 15, 2008; 1(15): re2 - re2.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
K. Imai and H. Yamamoto
Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics
Carcinogenesis, April 1, 2008; 29(4): 673 - 680.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. E. Chrencik, A. Brooun, M. I. Recht, G. Nicola, L. K. Davis, R. Abagyan, H. Widmer, E. B. Pasquale, and P. Kuhn
Three-dimensional Structure of the EphB2 Receptor in Complex with an Antagonistic Peptide Reveals a Novel Mode of Inhibition
J. Biol. Chem., December 14, 2007; 282(50): 36505 - 36513.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
K. Nosho, H. Yamamoto, T. Takahashi, M. Mikami, H. Taniguchi, N. Miyamoto, Y. Adachi, Y. Arimura, F. Itoh, K. Imai, et al.
Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers
Carcinogenesis, June 1, 2007; 28(6): 1364 - 1370.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. Davalos, H. Dopeso, J. Castano, A. J. Wilson, F. Vilardell, J. Romero-Gimenez, E. Espin, M. Armengol, G. Capella, J. M. Mariadason, et al.
EPHB4 and Survival of Colorectal Cancer Patients.
Cancer Res., September 15, 2006; 66(18): 8943 - 8948.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.